News

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...
Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...
Mounjaro's UK price will rise by 170% in September, prompting interest in cheaper alternatives like semaglutide for weight loss.
By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 15, 2025 (HealthDay News) — “Forever” PFAS chemicals might hamper a ...
By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...
Republican leaders pushed back on the DHHS approach. They also tied the dispute to broader state budget negotiations.
An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...
Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein ...
Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...
Are you a TRICARE beneficiary taking a drug for weight loss—such as a GLP-1 medication like Zepbound or Wegovy? Do you have ...
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.
One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...